Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Cash from Financing Activities (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Cash from Financing Activities for 8 consecutive years, with $77.5 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 1209.39% to $77.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $95.2 million through Dec 2025, up 88.63% year-over-year, with the annual reading at $95.2 million for FY2025, 88.63% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $77.5 million at Precision Biosciences, up from $1.7 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $92.9 million in Q2 2022, with the low at -$180000.0 in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $16.7 million, with a median of $5.3 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities skyrocketed 11592.68% in 2021, then plummeted 101.51% in 2022.
  • Over 5 years, Cash from Financing Activities stood at $8.4 million in 2021, then crashed by 102.15% to -$180000.0 in 2022, then surged by 1671.11% to $2.8 million in 2023, then surged by 109.34% to $5.9 million in 2024, then skyrocketed by 1209.39% to $77.5 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $77.5 million, $1.7 million, and $5.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.